Interleukin-6 (IL-6) is a 22-kDa cytokine produced by a variety of cells, most notably mononuclear phagocytes (1, 2) . Production and release of IL-6 has been documented to occur during various inflammatory conditions. Like the monokines IL-1 and tumor necrosis factor alpha (TNF-a), IL-6 mediates a wide array of biological activities. These include stimulation of lymphocyte proliferation, alterations in endothelial cell interaction with leukocytes, increased synthesis of acute-phase reactants by hepatocytes, and decreased growth by fibroblasts (1, 10, 12) . Levels of IL-6 in serum are elevated during septicemia and endotoxemia, thereby suggesting that it is an important mediator in these clinical syndromes (6, 7, 9, 11, 15) . Recent evidence suggests that IL-6 is responsible for some of the biological activities previously attributed to IL-1 and TNF-a during the host response to bacterial endotoxin (7, 11, 15) .
Previous studies by several laboratories, including our own, have documented the ability of recombinant IL-1 (rIL-1) and rTNF-ot to enhance resistance to a variety of experimental infections (3, 4, 13, 14) . We have shown that Listeria monocytogenes infection of mice is a useful experimental system for evaluating the effects of IL-la and TNF-a in host defense (4, 14) . If IL-6 indeed mediates many of the effects of IL-1 and TNF-a, one might predict that administration of rIL-6 provides substantial protection against experimental L. monocytogenes infection of mice. The purpose of the present study was to determine whether rIL-6 alone had a substantial effect on antilisteria resistance and whether rIL-6 in combination with rIL-1 and rTNF-a might modulate the resistance afforded by these monokines.
MATERIALS AND METHODS IL-6. The human rIL-6 used in this study (lot 1406-131) was generously provided by Genetics Institute (Cambridge, The highly purified human rTNF-a was a gift from Cetus Corporation (Emeryville, Calif.). This material had a biological activity of 21.5 x 10' U/mg in the L929 cell cytotoxicity assay.
Mice. The mice used in this study were 6-to 7-week-old male (C57BL/6 x DBA/2)F1 mice obtained from The Jackson Laboratory (Bar Harbor, Maine). They were certified by the supplier to be free of infection with adventitious viral agents. Mice were given food and water ad libitum and were maintained under sterile microisolator caps at the School of Veterinary Medicine Animal Care Facility.
L. monocytogenes infection. Experimental infection was assessed as we have described previously (14) . Log-phase L. monocytogenes EGD was stored as aliquots in tryptone phosphate broth with 20% glycerol at -70°C. For each experiment, an aliquot was thawed and diluted to a bacterial concentration of 4 x 104 organisms per 0.2 ml of pyrogenfree saline. This was injected intravenously (i.v.), along with the appropriate concentration of IL-6 or other monokines, into mice via the lateral tail vein. Positive controls included mice that received a dose of IL-la (0.2 ,ug) or TNF-a (1.0 ,g) known to stimulate significant protection. Mice that received L. monocytogenes without cytokine were included as a negative control. Three days after injection, the mice were killed by cervical dislocation and their spleens and portions of their livers were removed to separate sterile glass tissue grinders that contained 5.0 ml of cold phosphate-buffered saline. The tissues were homogenized and then serially diluted in sterile, distilled water. Appropriate dilutions were plated in duplicate on blood agar. The plates were incubated at 37°C for 24 h, and the number of colonies was counted. The results are expressed as the mean ± standard error of the mean (SEM) log1o L. monocytogenes per organ (3 or 4 mice per group).
RESULTS
Single bolus or repeated injections of rIL-6 do not enhance antilisteria resistance. In our first experiment, we assessed the effects of a range of concentrations of rIL-6 (0.2 to 2.5 ,ug per mouse), administered as a single i.v. bolus concomitant with bacterial challenge, on resistance to L. monocytogenes and deaths were recorded for 7 days following challenge. We observed no difference between the survival of control and rIL-6-treated listeria-infected mice (data not shown).
Effects of rIL-6 on antilisteria resistance mediated by rIL-la and rTNF-a. In a previous report we demonstrated that suboptimal doses of rIL-(x and rTNF-a, which by themselves had a minimal effect on antilisteria resistance, when injected in combination stimulated a substantial level of antilisteria resistance (14) . We, therefore, tested whether rIL-6 might have a similar ability to augment the resistance produced by treatment with suboptimal doses of rIL-ax and rTNF-ot. There was no significant elevation of antilisteria resistance in the spleens of mice that received rIL-6 (1 jig per mouse) i.v. together with suboptimal doses of rIL-at and rTNF-a (Table 1) . A small, but statistically significant, protective effect in the livers of mice was observed for mice that received rIL-6 and rTNF-a in combination (compared with rTNF-a alone) or rIL-6, rIL-lot, and rTNF-ot in combination (compared with that in mice that received rIL-a and rTNF-a in combination). We went on to determine whether coadministration of rIL-6 would alter the protection afforded by an optimal dose of rIL-la. Table 2 demonstrates that mice that received 1.0 jig of rIL-6 along with 0.2 p,g of rIL-la did not differ from mice that received 0.2 p,g of rIL-la alone. 
DISCUSSION
The results of this study indicate that rIL-6 does not enhance antilisteria resistance by itself and has a marginal ability to augment the effects of suboptimal concentrations of IL-lot and TNF-a when given in combination with these monokines. Although one might propose that these results were due to our using human IL-6 in mice, other investigators have reported that human IL-6 from the same source (Genetics Institute) stimulates an acute-phase response in mice (12) . Our results are generally consistent with the observations of Van der Meer et al. (16) , who found that rIL-6 increased survival but did not increase bacterial clearance in granulocytopenic mice infected with P. aeruginosa. These authors also reported that rIL-6 did not potentiate the protection offered by IL-1 in their model. Havell and Sehgal (8) recently reported that endogenous levels of IL-6 were elevated in the spleens and bloodstreams of L. monocytogenes-infected mice treated with an anti-TNF-ot monoclonal antibody. In that study, levels of IL-6 in plasma correlated with the severity of the infection and were largely independent of TNF-a release (8) .
Other evidence indicates that endogenous IL-6 levels correlate with active infection with a variety of microbes in both man and rodents (5-9, 11, 15) . In particular, it has been suggested that IL-6 is responsible for some of the lethal effects of endotoxemia and septic shock. Both IL-1 and TNF-a have been implicated as mediators responsible for the rise in IL-6 levels observed in these studies (7, 11, 15) . To the best of our knowledge, there is no compelling published evidence for the protective effects of rIL-6 in experimental infection models. This is in contrast to the monokines rIL-1 and rTNF-a, which offer substantial protection against a variety of infectious agents when administered to experimental animals (3, 14, 16) . Taken together, these findings suggest that, rather than being a major player in the protective host response to infection, IL-6 release represents an attempt by the host to repair tissue damage during microbial infection.
